Business
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer
About this update from In8bio, Inc.
[{"type":"text","content":"European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural killer (NK) cellsPatent portfolio broadly covers chemotherapy resistant engineering of innate immune cells for cellular therapy, providing the basis for IN8bio’s Drug Resistant Immunotherapy platform NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on advancing innovative gamma-delta T cell therapies utilizing its DeltEx platform, today announced the issuance of an additional European patent covering the composition of matter for IN8bio’s Drug Resistant Immunotherapy (DRI) platform. The patent broadens the Company’s intellectual property coverage of genetically engineered innate immune cells beyond gamma-delta T cells to include NK cells. Like gamma-delta T cells, NK cells respond directly to cellular stress and have shown promise in cellular therapy clinical trials. This newly issued patent bolsters the broad global patent portfolio that IN8bio has developed to support its core technology of chemotherapy resistance to enhance the efficacy of cellular therapies against solid tumor cancers. “Our previously issued patents in the United States and Europe broadly cover any genetic engineering that conveys chemotherapy resistance to gamma-delta T cells. This European patent expands our coverage to include NK cells, the other innate immune effectors that can respond to upregulated cellular stress to directly kill tumor cells,” said William Ho, CEO and co-founder of IN8bio. “Our unique DRI approach provides the ability to upregulate multiple NKG2D-ligands on the tumor cell surface, which allows for the targeting of heterogenous solid tumor cancers by innate immune cells.” The European patent (EP3552617), titled “Drug Resistant Immunotherapy for Treatment of a Cancer”, provides additional coverage for the DRI-based approach to cell engineering. Specifically, the patent covers the composition and use of DRI NK cells in oncology. This patent is part of a larger family of intellectual property that has been globally prosecuted by IN8bio, which continues to expand this portfolio and advance a pipeline of novel cellular therapy approaches for the treatment of cancer. These patents are co-owned by and exclusively licensed...